Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,353 Million (Small Cap)
20.00
NA
1.16%
-0.30
13.47%
2.75
Revenue and Profits:
Net Sales:
47 Million
(Quarterly Results - Jun 2025)
Net Profit:
14 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.28%
0%
-0.28%
6 Months
-3.16%
0%
-3.16%
1 Year
-12.52%
0%
-12.52%
2 Years
-37.24%
0%
-37.24%
3 Years
-36.05%
0%
-36.05%
4 Years
-50.46%
0%
-50.46%
5 Years
-52.52%
0%
-52.52%
Shanghai Hile Bio-Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.08%
EBIT Growth (5y)
33.09%
EBIT to Interest (avg)
1.32
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
0.18
Tax Ratio
13.73%
Dividend Payout Ratio
29.72%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.79%
ROE (avg)
6.32%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
2.75
EV to EBIT
55.69
EV to EBITDA
38.91
EV to Capital Employed
3.52
EV to Sales
14.36
PEG Ratio
0.05
Dividend Yield
1.16%
ROCE (Latest)
6.32%
ROE (Latest)
13.47%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
47.40
61.30
-22.68%
Operating Profit (PBDIT) excl Other Income
18.00
22.20
-18.92%
Interest
0.80
0.00
Exceptional Items
1.10
0.40
175.00%
Consolidate Net Profit
14.00
17.90
-21.79%
Operating Profit Margin (Excl OI)
275.40%
280.70%
-0.53%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -22.68% vs -35.47% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -21.79% vs -89.23% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
267.10
237.60
12.42%
Operating Profit (PBDIT) excl Other Income
55.70
32.40
71.91%
Interest
5.50
5.40
1.85%
Exceptional Items
-13.90
-16.50
15.76%
Consolidate Net Profit
181.60
50.00
263.20%
Operating Profit Margin (Excl OI)
61.50%
-35.80%
9.73%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 12.42% vs -19.92% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 263.20% vs -54.83% in Dec 2023
About Shanghai Hile Bio-Technology Co., Ltd. 
Shanghai Hile Bio-Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






